Osborne et al., Mol Cell Biol 2001
:
Repression of HLA-DRA promoter activation by HDAC activity likely involves a YY1 binding element located in the first exon of the HLA-DRA gene
Wang et al., J Immunol 2005
:
However, mycobacterial infection or TLR2 stimulation up-regulated expression of mammalian Sin3A, a corepressor that is required for MHC class II repression by HDAC Niesen et al., Biol Pharm Bull 2009
(Carcinoma, Non-Small-Cell Lung...) :
HDAC inhibitors that can be used to treat patients may augment the expression of tumor cell MHC class II , and the results suggest an opportunity to determine the immunological consequences of HDAC inhibitor treatment in tumor therapy